CA-H2O.AI
26.1.2021 17:21:12 CET | Business Wire | Press release
H2O.ai announces H2O AI Hybrid Cloud, an end-to-end AI platform that enables organizations to build rapidly, share, and use AI models and applications.
An innovative new platform, H2O AI Hybrid Cloud, empowers anyone to innovate and use AI to make better forecasts, streamline operations, reduce risk, and personalize customer experiences. It contains capabilities and automation across the entire data science lifecycle, including connecting to and preparing data, building and explaining models, deploying and operating models, and building and sharing AI applications.
“AI is central to AT&T’s mission to deliver wireless, broadband, and software-based video to our customers. We’ve deployed hundreds of AI models to support those products and services, such as to protect our customers by scoring transactions in real-time for the likelihood of fraud. Collaborating with H2O around their open source tools including H2O Wave and H2O AI Hybrid Cloud will let us expand those capabilities across AT&T.” – Mark Austin, Vice President of Data Science, AT&T
H2O AI Hybrid Cloud is deployed on Kubernetes, enabling customers to operate on any cloud, such as Microsoft Azure or on-premises infrastructure.
The platform features over 200 data connectors, automatic data visualization, automatic feature engineering, AutoML for tabular, time-series, text, image, and video data, and machine learning operations technology to help organizations govern and continuously improve models. H2O AI Hybrid Cloud is integrated with Snowflake, enabling data engineers to make AI models and score records using their preferred language -- SQL.
"It used to take large teams of expert data scientists months, or longer, to develop a single model, but today, with Snowflake’s extensibility capabilities and H2O's AutoML technology, data engineers can rapidly build and deploy their models and score records, all from within Snowflake using SQL." - Snowflake Director of Product Management, Torsten Grabs
The H2O AI Hybrid Cloud integrates with the recently released H2O Wave and is built for organizations that want to put AI into their business users’ hands. An open-source lightweight Python development framework, this platform makes it easy for developers, data scientists, and machine learning engineers to make sophisticated applications that leverage AI models.
“The future is no-touch, seamless, frictionless automation, supported by deep insights. Powered by H2O AI Hybrid Cloud, Arogya Mitra Sejati is bringing to life Arogya, a deep insights based automated supply chain platform - optimized for healthcare.” - Vijay Sarashetti, Cofounder and CTO, Arogya
H2O AI Hybrid Cloud also provides an AppStore, enabling organizations to publish and share the AI applications they build with H2O Wave. The AppStore deploys with a set of pre-built applications, such as Automatic Insights, Recommendations, and LIBOR, which organizations can use to put AI into production even faster.
“AI is transforming the world. Organizations are adopting AI at increasing rates and need holistic, open and automated platforms to make world-class AI models and applications rapidly. H2O AI Hybrid Cloud enables organizations to make AI for virtually any use case, streamline machine learning operations and democratize AI across the organization.” -Sri Ambati, CEO, H2O.ai
To meet hybrid and multi-cloud requirements for enterprises, Red Hat OpenShift will certify the platform early this year.
“Red Hat OpenShift, the industry’s leading enterprise-grade, fully-supported Kubernetes platform, is optimized for H2O Driverless AI and H2O Open Source, making it easier for customers to deploy and manage H2O.ai products across the hybrid cloud. We are working closely with H2O.ai as they seek to certify H2O AI Hybrid Cloud on OpenShift in order to continue building on this momentum.” - Joe Fernandes, Vice President and General Manager, Cloud Platforms, Red Hat
About H2O.ai
H2O.ai is a leading AI technology company that enables organizations to rapidly build world-class AI models and applications. We continue to reimagine what is possible with artificial intelligence and deliver new platforms and technologies to put responsible AI into the hands of more users.
Our vision is to democratize AI by making it easier for individuals to build and access world-class and responsible AI. To achieve this vision, we’re creating a culture of responsible and engaged makers: community, customers, partners, entrepreneurs, and our own “makers,” and we’re enabling them with the technology to “make.” H2O is a leading open-source data science and machine learning platform used by nearly half of the Fortune 500 and trusted by over 20,000 organizations and hundreds of thousands of data scientists around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005850/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
